Free shipping on all orders over $ 500


Cat. No. M1823
Perifosine Structure

KRX-0401, NKA17

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
2mg USD 40  USD40 In stock
5mg USD 70  USD70 In stock
10mg USD 100  USD100 In stock
25mg USD 200  USD200 In stock
50mg USD 330  USD330 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Perifosine is a novel p.o. bioavailable alkylphospholipid. Perifosine has displayed significant antiproliferative activity in vitro and in vivo in several human tumor model systems and has recently entered phase I clinical trials. Perifosine causes dose-dependent inhibition of protein kinase B/Akt phosphorylation and thus activation at concentrations causing growth inhibition of PC-3 prostate carcinoma cells. Only the myristoylated form of Akt (MYR-Akt), which bypasses the requirement for pleckstrin homology (PH) domain-mediated membrane recruitment, abrogated perifosine-mediated decrease of Akt phosphorylation and cell growth inhibition by perifosine. Perifosine decreases the plasma membrane localization of Akt, and this is substantially relieved by MYR-Akt along with relief of downstream compound effect on induction of p21(WAF1/CIP1). Perifosine does not directly affect phosphoinositide 3-kinase (PI3K), phosphoinositide-dependent kinase 1, or Akt activity at concentrations inhibiting Akt phosphorylation and membrane localization.

Product Citations
Customer Product Validations & Biological Datas
Source Drug Discoveries & Therapeutics 2020. Figure 4. perifosine (Abmole Bioscience Inc, Houston, TX, USA)
Method MTT assay
Cell Lines A549, H460, H322M, MCF-7, T47-D and MDA-MB-231 cells
Concentrations -
Incubation Time 72 h
Results The current study verified that the anti-cancer effect of perifosine was significantly enhanced by inhibiting miR-720 and that the anti-cancer effect of 5-Fu was significantly enhanced by inhibiting miR-887 in breast cancer cells
Protocol (for reference only)
Cell Experiment
Cell lines MM cells
Preparation method Growth inhibition assay. The inhibitory effect of perifosine, alone or combined with other agents, on MM cell growth was assessed by measuring 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT; Chemicon International, Temecula, CA) dye absorbance. Cells were pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hours of 24-hour and/or 48-hour cultures, followed by 100 μL isopropanol containing 0.04 N HCl. Absorbance was measured at 570/630 nm using a spectrophotometer (Molecular Devices, Sunnyvale, CA).
Concentrations 0~100 μM
Incubation time 24 or 48 h
Animal Experiment
Animal models MM.1S cells xenograft model in Immunodeficient BNX mice
Formulation 0.9% sodium chloride
Dosages daily (36 mg/kg) or weekly (250 mg/kg)
Administration oral
Chemical Information
Molecular Weight 461.66
Formula C25H52NO4P
CAS Number 157716-52-4
Solubility (25°C) Water 50 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Richardson PG, et al. Expert Opin Drug Metab Toxicol. Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.

[2] Lin X, et al. Neoplasma. Perifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-κB signaling pathway in a human breast cancer cell line.

[3] Richardson PG, et al. J Clin Oncol. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.

[4] Hideshima T, et al. Blood. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.

Related Akt Products

TAS-117 is a potent, selective, orally active allosteric Akt inhibitor (IC50 of 4.8, 1.6 and 44 nM for Akt1, 2 and 3, respectively).TAS-117 stimulates anti-myeloma activity and enhances lethal endoplasmic reticulum stress induced by proteasome inhibition.TAS-117 induces apoptosis and autophagy. autophagy).


NTQ1062 is an oral ATP-competitive Akt inhibitor being developed for cancer.


Borussertib is a covalent-allosteric inhibitor of protein kinase Akt with an IC50 of 0.8 nM and a Ki of 2.2 nM for WT Akt.

TIC10 Analogue

TIC10 Analogue is an analogue of TIC10, which inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. Phase 1/2.


WAY-277364 is a Allosteric Akt inhibitor.

Abmole Inhibitor Catalog

Keywords: Perifosine, KRX-0401, NKA17 supplier, Akt, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.